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ABSTRACT 
In this comparative biomarker study, we analysed 1768 serial sputum samples from 178 patients 
from 4 sites in South-East Africa. We show that tuberculosis Molecular Bacterial Load Assay (TB-
MBLA) reduces time-to-TB-bacillary-load-result from days/weeks by culture to hours and detects 
early patient treatment response. By day-14 of treatment, 5% of patients had cleared bacillary load 
to zero, rising to 58% by 12th week of treatment. Fall in bacillary load correlated with MGIT culture 
time-to-positivity (Spearmans r=-0.51, 95% CI (-0.56 to -0.46), p<0.0001). Patients with high pre-
treatment bacillary burdens (above the cohort bacillary load average of 5.5log10eCFU/ml) were 
less likely to convert-to-negative by 8th week of treatment than those with a low burden (below 
cohort bacillary load average), p=0.0005, HR 3.1, 95% CI (1.6-5.6) irrespective of treatment 
regimen. TB-MBLA distinguished the bactericidal effect of regimens revealing the moxifloxacin 
- 20mg rifampicin regimen produced a shorter time to bacillary clearance compared to standard-
of-care regimen, p=0.008, HR 2.9, 95% CI (1.3-6.7).  Our data show that the TB-MBLA could 
inform clinical decision making rapidly and expedite drug tuberculosis clinical trials.
INTRODUCTION
Tuberculosis is among the top 10 causes of death globally and has overtaken HIV/AIDS as a 
leading cause of death from a single infectious agent. An estimated 10 million fell ill of TB in 
2018 and approximately 1.5 million died[1]. Treatment is difficult, requiring a combination of four 
drugs and, depending on whether TB are drug-susceptible or -resistant, takes as long as six or 
twelve months to treat. To help health care workers managing TB make better decisions we need 
to develop effective methods to monitor the response to treatment. Such a marker of treatment 
response would reduce costs associated with prolonged care of patients who otherwise already 
converted to negative, and in tuberculosis clinical trials by speeding up drug development[2,3]. 
Effective methods would help identify those who are failing on treatment and require a change in 
therapy, or do not convert to negative early on in treatment and may require prolonged treatment 
period[4].
A high bacterial burden is known to be associated with a poor outcome but measuring it is difficult.  
A fall in bacterial burden is the most relevant marker of treatment response currently available, 
but culture is technically difficult to standardize and not all viable Mycobacterium tuberculosis 
(Mtb) bacilli are detected[5,6]. Alternative more rapid methods include mycobacterial DNA-
detection assays but prolonged DNA survival in the host after organisms have been killed 
precludes their use for treatment monitoring[7].  The TB-MBLA, a real-time reverse transcriptase 
quantitative polymerase chain reaction (RT-qPCR) uses more abundant 16S-rRNA as a target, 
increasing its sensitivity to accurately quantify Mtb viable bacillary load to as low as 10 CFU/ml 
and over many weeks of treatment[8,9]. Treatment response (change in bacillary load) can be 
detected as early as 3 days on treatment[8]. Here we report the first multi-centre evaluation of TB-
MBLA in comparison to standard-of-care culture methods for measuring TB treatment response 
in three high-burden sub-Saharan African countries. 
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METHODS
A total of 213 therapy naïve pulmonary tuberculosis patients were enrolled for treatment response 
assessment at four sites in Tanzania (site 1 & 2), Mozambique (site 3) and Malawi (site 4). The 
Tanzanian sites were part of the PanACEA MAMS-TB clinical trial (NCT01785186) and were on 
different regimens, all other participants were on standard of care HRZE/HR.  Serial patient 
sputum samples were collected weekly before and during treatment. Treatment response was 
measured over 12-week treatment period as change bacillary (bacterial) load (estimated (e) 
CFU/ml) measured by TB-MBLA, compared to culture positivity and/or culture time-to-positivity 
(TTP) by Lowenstein-Jensen (LJ) medium and the Mycobacterial Growth Indicator Tube (MGIT) 
culture. 
Spearman rank correlation (r) was used to assess relationship between change in bacillary load and 
TTP in response anti-TB therapy. Rate of sputum clearance for each patient was calculated as the 
SLOPE of the patient bacillary load and TTP over time using Microsoft Excel 2016 (y=bacillary 
load, x=time on treatment). Patient “conversion” was defined as a change from ‘positive’ to 
‘negative (two consecutive negative results)’ without subsequent reversion to ‘positive’ before the 
end of 12-week follow-up. The day of conversion was defined as the midpoint between last 
positive and first definite negative result. A negative result for TB-MBLA was considered at RT-
qPCR quantification cycle above 30 (zero bacillary load).  Patients with above the mean cohort 
bacterial load at baseline were categorised as “high bacterial load” and “low bacterial load” for 
those below the mean. Hazard ratio for conversion to negative by patients with high- versus low- 
baseline bacillary load, HIV+ or HIV- and/or treated with experimental regimens compared to 
standard-of-care (control) regimen was examined using Mantel-Cox and Gehan-Breslow-
Wilcoxon tests. One-way analysis of variance (ANOVA) was applied to examine inter-site 
variance in TB-MBLA performance.  In all analyses p values were considered significant at 
p<0.05. All statistical tests apart from SLOPE calculations were performed in Graphpad Prism v.6. 
Ethical approval for the study was obtained from relevant ethics committees in Tanzania 
(NIMR/HQ/R.8c/242), Mozambique (147/CNBS/14) and Malawi (P.08/13/1448) (detailed 
methods on line file 1) 
RESULTS 
Of the 213 patients, 178 (83·6%) patients completed 12-week follow-up were included in the 
analysis.  Males, 128 (71.9%) constituted the majority of cases, 47 (26.4%) were HIV positive and 
the median age of the whole study group was 33 years (IQR: 27-40 years). In 164 (92%) patients 
had susceptible TB (more details of patient characteristics online supplement figure 1). The rate 
of bacillary load clearance was high, ≥1 log10eCFU/ml/week in the first two weeks of therapy. As 
a result, 5% (9) patients had converted to zero bacillary load by day 14 of treatment. This number 
rose to 40% (71) and over half the cohort, 58.4% (104) by 8th and 12th week of treatment. Fall in 
bacillary load was inversely correlated with increase in TTP (Spearman r = -0.51, 95% CI (-0.56 
to -0.46), p<0.0001). The mean bacillary load at baseline (standard deviation) was 5.51.3 
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declining to 1.71.4 at week eight and 0.91.2 log10 eCFU/ml at week 12. MGIT culture TTP, 
median (range) at baseline was 5 (2-8) days, increasing to 21 (16-26) and 25(14-36) days by week 
8 and 12 respectively (Figure 1). 
While MGIT time-to-result increased with fall in bacterial load, from 5 to 25 days), TB-MBLA 
time-to-result was the same, 5±1h regardless of the patient bacillary load.  Patients with high 
baseline bacterial load were less likely to convert to negative by 8th and 12th week of treatment, 
p=0.0005, HR 3.1, 95% CI (1.6-5.6) and p=0.0008, HR 2.0, 95% CI (1.3-3.1) irrespective of 
treatment regimen and rate of sputum bacillary clearance in the first two weeks of treatment.  
Among patient characteristics, only HIV co-infection reduced the chance to clear bacillary load by 
12th week of treatment p=0.02, HR 2.1 95% CI (1.2-3.7). 
TB-MBLA showed that compared to control regimen, the rifampicin (RIF) 20mg/kg plus 
moxifloxacin and RIF 35mg/kg regimens had significantly higher bactericidal effect, 89% and 
56% conversion to negative by week 12 of treatment (Table 1). The RIF 35mg/kg regimen result 
is consistent with culture in the MAMS study[10], even though our study had additional HRZE 
patients from outside the study. TB-MBLA results were reproducible in different laboratory 
settings, ANOVA p>0.05 and not affected by contamination (Online supplement figures 2 and 3 
and table 1)
 
Control 
(RIFHZE) RIF20MHZ RIF35HZE RIF20QHZ RIFQHZ
Number analysed 32 18 17 16 16
Number converted by 
day 56 (week 8) 9 (28%) 11 (61%) 7 (41%) 6 (38%) 3 (19%)
Number converted by 
day 84 (week 12) 18 (56%) 16 (89%) 10 (59%) 9 (56%) 9 (56%)
Median time to 
conversion to negative 
(IQR)
77 (56-84) 56 (42-77) 70 (35-74) 74 (35-84) 70 (56-84)
Log-rank (Mantel-Cox) test     
Hazard ratio (95% CI)  -- 2.9 (1.3-6.7) 2.3 (1.0-5.2) 1.2 (0.5-2.9) 1.1 (0.5-2.5)
P value  -- 0.008 0.049 0.663 0.853
Gehan-Breslow-Wilcoxon test     
Hazard ratio (95% CI)  -- 2.3(1.4-6.3) 1.9 (1.1-4.9) 1.2 (0.5-2.8) 1.1 (0.5-2.4)
P value  -- 0.008 0.063 0.632 0.791
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5
Table 1 MBLA assessment of the clinical trial regimens compared to standard regimen. The 
RIF20MHZ and RIF35HZE treated cases had significantly shorter conversion time to negative than 
those treated with standard regimen. RIF=Rifampicin, M=Moxifloxacin, H=Isoniazid, 
Z=Pyrazinamide, E=Ethambutol and Q=SQ09.
DISCUSSION
Confirming the diagnosis and determining whether patient is responding to the prescribed therapy 
is crucial for healthcare workers managing tuberculosis patients.   In this study we have shown 
that TB-MBLA gives rapid bacillary load count, which responds to therapy in a pattern consistent 
with liquid culture, takes shorter time-to-result and is reproducible in different laboratory settings.  
Early determination of treatment response facilitates questions on adherence and/or drug 
resistance, and identifying patients at risk of failing treatment particularly those with high bacillary 
load. In addition, TB-MBLA simplifies evaluation of the impact of comorbidities such as HIV on 
bacillary load clearance during treatment. Compared to the current treatment monitoring methods, 
microscopy which is less sensitive and cannot distinguish viable from dead bacilli and culture with 
long time-to-result, we believe TB-MBLA has potentially higher utility for informing clinical 
decisions on individual patient management and facilitating rapid evaluation of anti-TB drugs in 
clinical trials. 
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Figure legends
Figure 1.  Bacteriological response to treatment measured by the TB-MBLA (A) and by MGIT (B) 
at four study sites. The curves indicate the average bacillary load reduction mirroring increase in 
culture time-to-positivity by all patients over a 12-week treatment period.  Dots represent individual 
patients at each site. Data points are widely spread in culture, which imply high culture result 
variability in late stages of treatment. Black curves with thick black dots represent Clinical trial Site 
1 and 2 cases, Red curves and red diamond clear symbols represent site 3 cases and Blue curves with 
black clear dots represent Site 4 cases (MGIT culture stopped at week 8). 
Page 8 of 22
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
7
Supplementary material
Online supplement Figure 1.  The study flow diagram.  Patients who died earlier on in the study, 
lost to follow-up, missing baseline sample, missing ≥2 treatment visit results and/or had no data at all 
were excluded from the analysis, leaving 178 patients.
Online supplement Figure 2. The reproducibility of TB-MBLA in different laboratory settings. A) 
the results of high BCG panel (n=24 per site), B) results of low concentration BCG panel (n=24 per 
site), and C) the extraction (internal control retrieved from patient samples as marker of extraction 
efficiency (n=1633 across the 4 sites). Each point represents an extracted sample and the red line is 
the median of the log eCFU/ml of the spiked extraction control.
Online supplement Figure 3. A comparison of MGIT culture and TB-MBLA results. Orange and 
green bars are cases with definitive MBLA positive or negative result but indeterminate MGIT 
culture result due to contamination that grew in number in late stages of treatment. 
Online supplement table 1: The MGIT and LJ culture results showing the increasing 
contamination rates as patients progressed on treatment. There were more contaminations 
in MGIT than LJ.
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Treatment response over the 12-week period 
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Tuberculosis bacillary load, an early marker of disease severity and treatment 
response: the utility of tuberculosis Molecular Bacterial Load Assay    
 
Key messages 
 
What is the key question? 
What is the utility of using TB-MBLA to monitor TB treatment response compared to standard 
culture methods? 
 
What is the bottom line? 
The TB-MBLA measured bacillary load falls in a manner consistent with increasing culture-time-
positivity as the patient responds to anti-TB therapy but unlike culture, the TB-MBLA quantitative 
result is available in hours instead of days or weeks, unhampered by contamination and 
reproducible in diverse settings. 
 
 
Why read on? 
Fourteen days into treatment, 5% of the patients had converted to negative with zero bacillary load 
while over half of all the patients had done the same by 12th week of treatment, revealing that most 
TB patients convert to negative early in treatment and may not require prolonged stay on anti-TB 
therapy.  These results show the power of a rapid bacillary load result delivered by TB-MBLA to 
inform individual treatment decisions, early detection of poor treatment responders who need 
longer time on therapy and/or change of course for those on ineffective therapy. 
 
INTRODUCTION 
 
Tuberculosis (TB) is among the top 10 causes of death globally and has taken over HIV/AIDS as 
a leading cause of death from a single infectious agent. An estimated 10 million suffered TB in 
2018 and approximately 1.5 million died[1]. Treatment is difficult requiring combination of four 
drugs and depending on the form of TB, susceptible or resistant takes as long as six or twelve 
months to treat. The number of patients who require retreatment is high and 18% of these account 
for the half million drug-resistant tuberculosis cases[1]. To help health care workers managing 
tuberculosis (TB) make better decisions we need to develop effective methods to monitor the 
response to treatment[2]. Such a marker of treatment response would reduce costs in tuberculosis 
clinical trials and speed drug development[3,4]. Effective methods would help identify those who 
convert to negative early on in treatment and don’t require prolonged treatment period and vice 
versa for those failing on treatment[5]. 
 
Definitive diagnosis of tuberculosis depends on the culture of Mycobacterium tuberculosis, the 
current gold standard.  For most TB control programs there is, however, limited availability of 
culture due to the cost of high containment laboratories, staff training and reagent supply. With a 
culture-based approach results are available too late to inform timely clinical decision making.  
Factors such as specimen transport, type of media, and chemical decontamination to eliminate 
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 2 
non-mycobacterial flora compromise the consistency of culture. In addition, culture time-to-result 
is long and depends on the level patient TB burden. This means that low burden patients wait 
longer for results than their high burden counterparts.  Sputum culture conversion is only weakly 
predictive of long-term patient outcome for regimens but not individuals limiting its utility to 
individual and clinical trial management[6]. Smear microscopy, an approved routine care 
treatment monitoring is less sensitive and cannot distinguish between viable and dead bacilli[7]. 
 
Enumeration of viable mycobacteria during therapy is probably the most accurate biomarker of 
treatment response currently available, but culture is technically difficult to standardise and not all 
viable Mtb bacilli are detected[8,9]. Alternative more rapid methods include mycobacterial DNA-
detection assays but prolonged DNA survival in the host after organisms have been killed 
precludes their use for treatment monitoring[10].   Messenger RNA (mRNA) targets, with a shorter 
half-life than DNA including fbpB antigen 85B, hspX, and icl, have been tested as treatment 
response biomarkers.  Their decline during treatment mirrors traditional M. tuberculosis colony 
counting[11–13] but, as mRNA exists at low concentrations, mRNA based assays reach their limit 
of detection rapidly when patients are still TB culture positive[12,13].  These assays are valuable 
for following early responses, but less effective for monitoring over a longer period of treatment. 
 
The tuberculosis Molecular Bacterial Load Assay (TB-MBLA), a real-time reverse transcriptase 
quantitative polymerase chain reaction (RT-qPCR) uses more abundant 16S-rRNA as a target and 
can accurately quantify M. tuberculosis viable bacillary load over many weeks of treatment[14] 
and could replace solid culture[15].  Here we report the first multi-centre evaluation of the TB-
MBLA in comparison to standard methods in three high-burden countries in sub-Saharan Africa 
and show that it assesses disease severity and patients’ response to treatment in real-time to inform 
clinical decision and is reproducible across different laboratory settings. 
  
METHODS 
 
Sites, patients and sample schedule 
Tanzania (Site 1 and 2): Patients were recruited from the PanACEA Multi-Arm Multistage 
(MAMS) TB trial sites, Kibong’oto National Tuberculosis Hospital-Kilimanjaro Clinical Research 
Institute (KCRI) and National Institute of Medical Research at Mbeya Medical Research Centre 
(NIMR-MMRC)[16]. Tuberculosis was confirmed by sputum smear microscopy or GeneXpert.  
Early morning and spot sputum samples were collected at enrolment and weekly for 12 weeks. 
Culture was by Lowenstein Jensen (LJ) media and in the Mycobacterial Growth Indicator Tube 
(MGIT) liquid culture system and spot sputa were used for TB-MBLA on site. If insufficient 
material was available, the specimen was used for MGIT liquid culture.   
 
Mozambique (Site 3): Sputum smear and GeneXpert MTB/RIF positive patients, irrespective of 
HIV status were recruited from the Maputo Tuberculosis Trial Unit (MaTuTU). MDR-TB was not 
an exclusion criterion. Patients received WHO recommended treatment for susceptible or MDRTB 
as appropriate. Early morning and spot sputum samples were collected at enrolment and then one, 
two four, eight and 12 weeks.  
 
Malawi (Site 4): Sputum smear or GeneXpert MTB/RIF positive patients were recruited from the 
TB clinic, Queen Elizabeth Central Hospital, College of Medicine, Blantyre. All patients except 
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 3 
two retreatment cases received WHO recommended standard treatment for susceptible disease. 
Early morning and spot sputa were collected at enrolment, then 2,4,6,8 and 12 weeks.  
 
Ethics 
Consent for collection and laboratory evaluation of samples from MAMS-TB study was obtained 
from National Institute of Medical Research (NIMR) for the Tanzanian sites, NIMR/HQ/R.8c/242.  
Approval was also obtained from  Instituto Nacional de Saude (INS) Institutional Review Board 
and National ethics committee for the Mozambique site, 147/CNBS/14 and College of Medicine 
Research Ethics Committee (COMREC) University of Malawi for the Malawian site, 
P.08/13/1448.  
 
 
Molecular and Microbiological methods 
Culture based measures: All sputum samples were tested by quantitative microscopy, culture on 
Lowenstein-Jensen medium and MGIT as previously described[12,13]. Positive MGIT cultures 
were tested for acid fast bacilli (AFB) positivity and contamination using Ziehl Neelsen (ZN) 
staining and blood agar respectively. AFB and Antigen MPT64 negative but blood agar positive 
cultures were considered contaminated (indeterminate). AFB and MPT64 positivity confirmed 
presence of Mycobacterium tuberculosis (Mtb) whilst blood agar positivity result within 24h 
confirmed presence of contaminating flora.  
 
 
Tuberculosis Molecular Bacterial Load Assay (TB-MBLA): 
Sputum aliquots (1ml volume) were preserved for TB-MBLA by diluting 1:4 in 50% guanidine 
thiocyanate (GTC) w/w, 0·1M Tris HCl pH 7·5 and 1% -mercaptoethanol v/v then stored at -
80°C until testing. Testing was done in batches with majority of samples tested between 1-4 weeks 
from collection. Prior to RNA extraction,  samples were thawed at room temperature and internal 
control (100l) added. Mtb cells were harvested by centrifugation  3000 g for 30 minutes and total 
RNA extracted using the RNA Pro Blue kit (MP Biomedicals following manufacturer’s 
instructions[11]. Reverse transcriptase qPCR of the RNA was performed as described previously 
using RotorGene 5plex platform (Qiagen)[11]. Primers and Taqman dual labelled probes targeting 
M. tuberculosis and the internal control were procured from Eurofin Genomics, Germany (Note: 
the oligos have been incorporated into the TB-MBLA kit and cannot be published).  Standard 
curve was used to convert quantification cycles (Cq) into bacterial (bacillary) load (estimated 
colony forming units per ml (eCFU/ml) and log transformed at a factor of log10.  A high (10
7 
CFU/ml) and low (103 104 CFU/ml) positive control (BCG NCTC 5692) and negative control of 
RNase free molecular grade water were included in each assay run. The limit of detection of TB-
MBLA was considered at 30 Cq, equivalent to 10 eCFU/ml bacillary load. 
 
Quality assurance and applicability of the MBLA assay in different laboratory environments: 
To verify the quality assurance, reproducibility and applicability of the different settings we 
analysed how participating laboratories processed the externally supplied standard BCG positive 
control panels. Two panels of material containing either a high concentration, 107 CFU/ml and low 
concentration, 104 CFU/ml (n=24) were supplied by the University of St Andrews TB laboratory 
to all participating sites. Each laboratory independently conducted RNA extraction and qPCR and 
analysis. 
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Analysis 
Correlation of TB-MBLA and MGIT was determined using Spearman rank correlation (r). 
Treatment response was defined as a change in bacterial load measured by TB-MBLA, time to 
culture positivity (TTP) by liquid MGIT and/or positivity/negativity of TB-MBLA, MGIT and LJ. 
Rate of sputum clearance was calculated as the SLOPE of the patient bacillary load and TTP 
treatment response curves (y=bacillary load and x=time on treatment) using Microsoft Excel 2016. 
Patient “conversion” was defined as a change from ‘positive’ to ‘two consecutive negatives’ 
without subsequent reversion to ‘positive’ before the end of follow-up. “Non-conversion” was 
defined as persistent or recurrently positive samples by the final visit on day 56 and 84 for 2-
months and 3-months outcome respectively. The day of conversion was defined as a midpoint 
between last positive and first definite negative result.  One-way analysis of variance (ANOVA) 
was applied to examine inter-site variance in TB-MBLA performance. In all analyses p values 
were considered significant at p<0.05. Apart from SLOPE, all statistical analyses were performed 
with GraphPad Prism v.6. 
 
RESULTS  
 
TB-MBLA measured bacillary load inversely correlates with culture time to positivity in 
TB patients 
 
Patients and samples: A total of 213 anti-tuberculosis treatment naïve patients were enrolled for 
treatment response monitoring using TB-MBLA in comparison with culture at four study sites. 
Out of the 2103 cases, 101 were under the MAMS clinical trial sites in Tanzania[16] whereas 112 
cases were enrolled from routine practice sites in Mozambique and Malawi. 178 (83·6%) 
completed the 12-week treatment follow-up and were included into the analysis: Tanzania 100 
(55·9%), Mozambique 58 (32.8%), and Malawi 20 (11.3%) (supplementary figure 1).  Males, 128 
(71.9%) constituted the majority of cases, 47 (26.4%) were HIV positive and the median age of 
the whole study group was 33 years (IQR: 27-40 years). A total of 1768 serial samples were tested 
over a period of 12 weeks of treatment follow-up. In 164 (92%) patients, the organisms were fully 
susceptible while 14 patients had drug resistance: 7 (4%) were pyrazinamide monoresistant, 3 
(1.7%) were polyresistant to isoniazid and pyrazinamide while 4 (2.5%) were multidrug resistant 
TB (MDR-TB) and managed with MDR regimen including kanamycin, levofloxacin, ethionamide, 
cycloserine, and pyrazinamide.  
 
 
Treatment response and implication of high pre-treatment bacterial burden: Over the 12 weeks of 
treatment there was a steady decline in bacillary load at a rate of sputum clearance, 
0.4log10eCFU/ml/week corresponding to 1.1 days/week MGIT culture time to a (TTP). The rate 
of sputum bacillary load clearance was faster >1log10eCFU/ml/week in the first two weeks of 
treatment. As a result, 5% (9) patients had zero bacillary load by week two of treatment. The 
number of patients converting to zero bacterial load rose to 40% (71) and 58.4% (104) by 8th and 
12th week of treatment. Fall in bacillary load was inversely correlated with increase in TTP, 
Spearman r = -0.51, 95% CI (-0.56 to -0.46), p<0.0001. The mean bacillary load (standard 
Page 14 of 22
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 5 
deviation) at baseline, 5.·51.·3 declining to 1.·71.·4 at week eight and 0.·91.·2 log10 eCFU/ml 
at week 12. MGIT culture TTP, median (range) at baseline was 5 (2-8) days, increasing to 21 (16-
26) and 25(14-36) days by week 8 and 12 respectively. Using logistic regression, we found that 
patients with high baseline bacterial load (≥6log10eCFU/ml) were less likely to convert to negative 
by 8th week of treatment, OR 1.5, p=0.002 and this was independent of their rate of clearance in 
the first 2 weeks of treatment (figure 1 main paper). 
 
Despite the higher number of males in the study, their mean bacterial load 5.6 ± 0.1 and time-to-
conversion 50.8± 0.9 days in the first 2 months of treatment did not differ from that of females, 
5.4 ± 0.2, 47.1±2.0 days, Unpaired t test, p=0.37 and 0.06 respectively. 
 
 
 
Time to result: The TB-MBLA result was available in 5±1h from the time the sample was received 
at the laboratory and was independent of the patient bacillary load. In contrast, the time-to-culture 
result increased with decline in bacterial load, starting from 5 days at baseline to 25 days at 12 
weeks of treatment.  
 
 
 
 
TB-MBLA concurred with culture on distinguishing the bactericidal effect anti-TB regimens  
 
We analysed the performance of TB-MBLA for distinguishing the bactericidal effect of four 
experimental regimens compared to the control on a cohort of 100 MAMS trial patients in 
Tanzania[16]. The four regimens were different combinations of high dose rifampicin (RIF) 
20mg/kg and 35mg/kg, moxifloxacin (M), and SQ109 compared to standard-of-care drugs, RIF, 
Isoniazid (H), pyrazinamide (Z), and ethambutol (E). Percent conversion to negative (two 
consecutive zero bacterial load results without reversion to positive) was calculated. Conversion 
in RIF20MHZ, 89% and RIF35HZE, 59% were higher than the control RIFHZE, 56% at week 12 
of treatment. Using Mantel-Cox and Gehan-Breslow-Wilcoxon tests we asked whether time to 
conversion to negative was different between the experimental regimens and standard-of-care 
(control) regimen. RIF20MHZ had significantly shorter time-to-negative conversion, p=0.008 for 
both tests whilst RIF35HZE was weakly significant, p=0.049 in the Mantel-Cox test and trend, 
p=0.06 for the Gehan-Breslow-Wilcoxon (Table 1 main paper) 
 
TB-MBLA is robust and reproducible in different laboratory settings 
 
A TB monitoring test for clinical use needs to be performed consistently in different clinical 
laboratories.  To achieve this, we analysed variance of the qPCR results of standard BCG panels 
(high concentration, log7- and low concentration, log4- CFU/ml) and extraction (internal) control, 
log5 CFU per patient sample independently processed at the four study sites. The measured 
bacterial load from standard BCG panels were consistent between sites, median (IQR) 7.1(7.0-
7.6), 7.1 (6.9-7.6), 7.4 (6.9-7.8), 7.4 (7.2-7.7) log10 eCFU/ml, coefficient of variation (CV), 4.87%, 
4.39%, 7.26%, 4.96% for the high concentration panel (supplementary figure 2A) and 3.4 (3.1-
3.7), 3.5 (3.1-4.1), 3.3 (3.0-3.8), 3.6 (3.3-3.8), CV 15.80%, 18.70%, 15.36%, 12.43% for low 
Formatted: Font: (Default) Times New Roman
Page 15 of 22
https://mc.manuscriptcentral.com/thorax
Thorax
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 6 
concentration panel (supplementary figure 2B) for sites 1, 2, 3 and 4 respectively. Similarly, the 
internal control was consistently retrieved, median (IQR) 4.4 (3.5-5.1), 3.8 (3.4-4.3), 4.2 (3.7-4.6), 
3.9 (3.1-4.5) and CV 19.10%, 16.42%, 13.75%, 19.15% for the four sites respectively. Taken 
together, the average retrieval of internal control was 4.1±0.7 log10eCFU/ml, which is equivalent 
to 82% (4.1/5.0 log10eCFU/ml) RNA extraction efficiency (supplementary figure 2C). The 
ANOVA probability value was >0.05 between sites for both positive and internal extraction 
control.  
 
TB-MBLA is not affected by contaminating flora in patient sputum 
 
At baseline, 171 (98%) patients generated quantitative TB-MBLA eCFU/ml and MGIT TTP 
results. The number of dually positive samples decreased steadily as the number of positives 
declined and by week twelve only 16 (10.7%) were positive by both assays. A total of 232 (14.8%) 
samples were MBLA positive - MGIT contaminated including 32 (21.3%) from week 12.   No 
patients were both negative by MBLA and MGIT at baseline, but this figure rose to 20 (13.3%) by 
week 12. “MBLA negative, MGIT contaminated” was found in 195 (12.4%) specimens, including 
61 (40.7%) at week 12. The rate of culture contamination increased with time on treatment 
resulting in fewer MGIT culture samples available for TTP analysis, 19 (11%) by week 12 of 
treatment. In total 427 (27.2%) samples with a definite “positive” or “negative” result on MBLA 
were lost to contamination by MGIT.  Only 70 (4.5%) samples were MBLA negative and MGIT 
TTP positive (putative MBLA false negative). In comparison, 103 (6.57%) were MBLA eCFU/ml 
positive but MGIT negative (putative MGIT false negative) (supplementary Figure 3).  
 
Solid (LJ) cultures only were less prone to contamination than MGIT at all time-points but less 
sensitive than MGIT and TB-MBLA (supplementary table 1).  
  
 
Number of samples (%) in weeks 
Week 0  1-2  3-4  5-6  7-8  9-10  11-12 Total 
MGIT 
Positive 171 (96) 278 (91) 197 (81) 117 (56) 92 (39) 42 (25) 40 (17) 937 (60) 
Negative 2 (1) 11 (4) 10 (4) 22 (11) 51 (22) 44 (26) 63 (26) 203 (13) 
Contaminated 1 (1) 15 (5) 36 (15) 70 (33) 94 (40) 84 (49) 
137 
(57) 
427 (27) 
LJ 
Positive 115 (77) 186 (74) 112 (52) 71 (38) 37 (23) 19 (10) 10 (5) 554 (40) 
Negative 27 (18) 60 (24) 95 (44) 105 (56) 
115 
(71) 
160 
(86) 
166 
(90) 
768 (56) 
Contaminated 6 (4) 4 (2) 7 (3) 10 (5) 9 (6) 7 (4) 8 (4) 51 (4) 
Supplementary table 1: The MGIT and LJ culture results showing the increasing 
contamination rates as patients progressed on treatment. There were more contaminations 
in MGIT than LJ. 
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DISCUSSION 
 
The most important questions facing healthcare workers managing patients with tuberculosis is to 
confirm the diagnosis and to determine whether the patient is responding to the prescribed therapy.   
Failure to respond may be due to multiple factors including poor adherence, poor absorption of 
drugs, or a drug-resistant infecting organism. Bacillary load is an established biomarker for disease 
severity and treatment outcome[17–19], yet the current diagnostic methodologies do not provide 
the information to address crucial clinical questions in a meaningful time-frame. In this paper, we 
have shown that TB-MBLA gives rapid bacillary load count, which responds to therapy in a pattern 
consistent to liquid culture, is reproducible in different laboratory settings, more sensitive than 
culture and reduces time-to-result from days or weeks to hours. We believe these properties 
increase TB-MBLA’s utility for informing clinical decisions on individual patient management 
drugs and facilitating rapid evaluation of anti-TB drugs in clinical trials. From the perspective of 
the treating healthcare worker, the TB-MBLA provides a readily understandable result, a number 
of viable bacteria compared to time-to-positivity.  
 
When plotted as a patient journey, the decline in bacillary load is an inverse image of the MGIT 
TTP results over the first three months of treatment[14].  A recent study has further confirmed this, 
demonstrating that TB-MBLA is more consistent to culture in detecting viable bacilli than Xpert 
MTB/RIF and smear microscopy[20]. This suggests that they are monitoring broadly similar 
measures in the viable count. In the first few weeks following the initiation of treatment, it is 
important to understand whether the patient is responding.  Radiological appearances do not 
resolve in a timely or reproducible way[21].  MGIT is a semi-quantitative measure of viable count 
as the patient responds to therapy, as the time to a positive culture result increases, the time taken 
to report a useful result increase proportionately. Direct quantification of M. tuberculosis RNA in 
the sample means that the level of patient bacterial burden does not influence the TB-MBLA time-
to-result in the laboratory. In contrast time to result in culture depends on patient bacterial burden 
of which low burden patients wait longer to receive their results.  
 
Like culture, molecular bacillary load clearance is biphasic, faster in the first 14 days of treatment 
and slow in the subsequent weeks of treatment follow-up. This may be explained by the hypothesis 
that anti-TB drugs work by fast clearance of the actively growing bacilli and slowly for th  dormant 
(persister) population[22]. High baseline bacterial load was predictive of failure to convert to 
negative at 8 weeks of treatment, consistent with previous findings with culture [23–25]. All the 4 
MDRTB patients were among those who did not convert to negative by week 8, however, this was 
too small a number to make any comparative modelling of the impact of MDRTB on treatment 
response measured by TB-MBLA. Among the patient characteristics, only HIV coinfection 
reduced the chance to convert to negative (zero bacillary load) by 12th week of treatment. This 
observation contrasts earlier studies where bacterial load clearance was not different between HIV-
infected and HIV-uninfected patients[26,27], and thus requires further investigation.  
 
TB-MBLA largely concurred with MGIT culture on the shorter time to conversion of the clinical 
trial patients treated with high dose rifampicin regimen. However, in this cohort of 100 Tanzanian 
patients, the moxifloxacin-20mg/kg RIF regimen gave a significantly shorter time to conversion 
compared to HZE-35mg/kg RIF regimen that emerged the most effective regimen according to the 
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 8 
MAMS study findings. The MAMS results were based on culture conversion of the whole MAMS 
study cases from Tanzania (part of this study) and South Africa[16]. The better performance of the 
moxifloxacin regimen may be explained by the reported rapid bactericidal effect in the early weeks 
of treatment but poor sterilizing effect in the continuation phase of treatment[28]. The limitation 
of this comparison is that the two tests (TB-MBLA and MGIT culture) were not performed on 
equal number of cases and for the same length of treatment follow-up. Future larger trials involving 
both tests will give a more accurate comparison of their ability to assess the bactericidal effect of 
anti-TB therapy in relation to treatment outcomes. 
 
To be useful and accessible to a wider community, it is crucial that the diagnostic test is robust and 
its results are reproducible.  This paper shows the TB-MBLA test results are reproducible in 
different laboratory settings. We have shown previously that the tuberculosis molecular bacterial 
load assay  is species specific [14,29,30], providing the healthcare worker with both confirmation 
of the tuberculosis diagnosis and response to therapy. The use of the extraction (internal) control 
in TB-MBLA enables normalisation of results based on the amount retrieved compared to the 
amount that was spiked in prior to extraction process. The 82% extraction efficiency is consistent 
to the one reported by Ratnam et al at centrifugation force, 3005 – 3895g[31]. The loss in extraction 
could be attributed to the poor sedimentation of mycobacteria during the initial centrifugation step 
as reported by several studies[31–34].   
 
Despite being a gold standard, culture results are compromised by growth of non-TB flora in 
sputum. Attempts to remove these flora using sodium hydroxide and/or  suppress them by 
antibiotics in liquid culture, malachite green in Lowenstein Jensen reduce the viable bacterial load 
and increase risk of variation in laboratory performance and result[35]. Contaminated samples are 
more likely at late stages of treatment, a time when patients’ bacillary load has fallen significantly 
and they have greater difficulty producing quality sputum. In our data we show the impact of this 
effect with significant loss of TTP data points particularly at late stages of treatment. This further 
compromises the utility of culture to inform clinical decision at later timepoints. TB-MBLA is not 
affected by contamination and produced a quantitative result for the M. tuberculosis viable count 
at both early and late stages of treatment.  
 
This study has highlighted several strong attributes of TB-MBLA but there are limitations that 
require more studies to address.  A study evaluating many more patients with resistant disease that 
are more likely to respond poorly to therapy is needed to establish a marker for poor response early 
in treatment. For example, how much bacillary load the patient should clear in the first days of 
treatment in order to be regarded as good or poor responder?  Secondly, what is the effective testing 
frequency that usefully maps patient’s treatment response and their clinical outcomes?  More 
optimisation studies to explain discordant results between culture and TB-MBLA and to simplify 
the assay so that it is easy to perform with minimal hands on time and available at affordable cost.   
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Figure legends 
 
Supplementary figure 1.  The study flow diagram.  Patients who died earlier on in the study, lost 
to follow-up, missing baseline sample, missing ≥2 treatment visit results and/or had no data at all 
were excluded from the analysis, leaving 178 patients. 
Supplementary figure 2. The reproducibility of TB-MBLA in different laboratory settings. A) the 
results of high BCG panel (n=24 per site), B) results of low concentration BCG panel (n=24 per site), 
and C) the extraction (internal control retrieved from patient samples as marker of extraction 
efficiency (n=1633 across the 4 sites). Each point represents an extracted sample and the red line is 
the median of the log eCFU/ml of the spiked extraction control. 
 
Supplementary figure 3. The concordance and discordance of MGIT culture and TB-MBLA 
results. Orange and green bars are cases with definitive MBLA positive or negative result but 
indeterminate MGIT culture result due to contamination that grew in number in late stages of 
treatment.  
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